Bezafibrate (BZA), a PPAR-α agonist, has been used widely in the treatment of hyperlipidemia and could also attenuate hepatic steatosis and modulate insulin resistance and obesity [17]. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.